|
|
 |
|
Total Number of Holdings (excluding cash): 50
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
309,254 |
$88,335,312.56 |
7.74% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
68,552 |
$87,298,229.92 |
7.65% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
2,786,339 |
$83,673,760.17 |
7.33% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
298,296 |
$78,693,467.76 |
6.89% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
536,674 |
$77,962,631.98 |
6.83% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
183,012 |
$45,879,278.28 |
4.02% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,401,556 |
$43,228,008.00 |
3.79% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
270,934 |
$42,276,541.36 |
3.70% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
514,258 |
$41,670,325.74 |
3.65% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
92,226 |
$40,511,192.76 |
3.55% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
68,966 |
$40,517,525.00 |
3.55% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
49,624 |
$39,948,312.48 |
3.50% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
72,813 |
$38,148,915.09 |
3.34% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
318,194 |
$36,818,227.74 |
3.23% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
593,463 |
$36,486,105.24 |
3.20% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
441,679 |
$28,501,545.87 |
2.50% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
126,061 |
$26,977,054.00 |
2.36% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
91,571 |
$24,671,058.82 |
2.16% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
159,191 |
$19,999,165.33 |
1.75% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
27,316 |
$18,279,730.80 |
1.60% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
93,682 |
$13,368,421.40 |
1.17% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
38,364 |
$13,249,774.68 |
1.16% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
232,196 |
$12,991,366.20 |
1.14% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
568,755 |
$12,808,362.60 |
1.12% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
56,791 |
$12,722,887.73 |
1.11% |
| Iovance Biotherapeutics, Inc. |
IOVA |
462260100 |
Biotechnology |
674,582 |
$9,504,860.38 |
0.83% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
39,263 |
$7,856,526.30 |
0.69% |
| Caris Life Sciences, Inc. |
CAI |
142152107 |
Biotechnology |
216,212 |
$6,918,784.00 |
0.61% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
315,481 |
$6,429,502.78 |
0.56% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
88,252 |
$6,314,430.60 |
0.55% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
19,394 |
$5,886,660.82 |
0.52% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
34,662 |
$5,860,650.96 |
0.51% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
159,094 |
$5,805,340.06 |
0.51% |
| Adaptive Biotechnologies Corporation |
ADPT |
00650F109 |
Biotechnology |
221,151 |
$5,641,562.01 |
0.49% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
61,690 |
$5,572,457.70 |
0.49% |
| Tango Therapeutics, Inc. |
TNGX |
87583X109 |
Biotechnology |
241,300 |
$5,631,942.00 |
0.49% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
39,647 |
$5,547,408.24 |
0.49% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
101,504 |
$5,498,471.68 |
0.48% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
117,282 |
$5,117,013.66 |
0.45% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
46,393 |
$5,138,488.68 |
0.45% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
37,307 |
$5,164,408.01 |
0.45% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,343 |
$4,779,344.50 |
0.42% |
| Oruka Therapeutics, Inc. |
ORKA |
687604108 |
Biotechnology |
59,500 |
$4,768,925.00 |
0.42% |
| Corcept Therapeutics Inc. |
CORT |
218352102 |
Pharmaceuticals |
48,624 |
$4,174,856.64 |
0.37% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
83,143 |
$4,163,801.44 |
0.36% |
| Dianthus Therapeutics, Inc. |
DNTH |
252828108 |
Biotechnology |
52,196 |
$4,007,608.88 |
0.35% |
| Enliven Therapeutics Inc. |
ELVN |
29337E102 |
Biotechnology |
95,203 |
$3,952,828.56 |
0.35% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
66,892 |
$3,881,073.84 |
0.34% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
190,629 |
$3,761,110.17 |
0.33% |
| Liquidia Technologies, Inc. |
LQDA |
53635D202 |
Biotechnology |
80,844 |
$3,447,996.60 |
0.30% |
| US Dollar |
$USD |
|
Other |
1,561,710 |
$1,561,710.35 |
0.14% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|